Recce Pharmaceuticals Management
Management criteria checks 3/4
Recce Pharmaceuticals' CEO is James Graham, appointed in Aug 2020, has a tenure of 9.17 years. total yearly compensation is A$774.73K, comprised of 71.1% salary and 28.9% bonuses, including company stock and options. directly owns 4.44% of the company’s shares, worth $2.98M. The average tenure of the management team and the board of directors is 4 years and 5.7 years respectively.
Key information
James Graham
Chief executive officer
AU$774.7k
Total compensation
| CEO salary percentage | 71.1% |
| CEO tenure | 4yrs |
| CEO ownership | 4.4% |
| Management average tenure | 4yrs |
| Board average tenure | 5.7yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2023 | n/a | n/a | -AU$11m |
| Sep 30 2023 | n/a | n/a | -AU$12m |
| Jun 30 2023 | AU$775k | AU$551k | -AU$13m |
| Mar 31 2023 | n/a | n/a | -AU$14m |
| Dec 31 2022 | n/a | n/a | -AU$15m |
| Sep 30 2022 | n/a | n/a | -AU$13m |
| Jun 30 2022 | AU$548k | AU$328k | -AU$11m |
| Mar 31 2022 | n/a | n/a | -AU$10m |
| Dec 31 2021 | n/a | n/a | -AU$8m |
| Sep 30 2021 | n/a | n/a | -AU$11m |
| Jun 30 2021 | AU$2m | AU$294k | -AU$14m |
| Mar 31 2021 | n/a | n/a | -AU$13m |
| Dec 31 2020 | n/a | n/a | -AU$13m |
| Sep 30 2020 | n/a | n/a | -AU$9m |
| Jun 30 2020 | AU$216k | AU$187k | -AU$4m |
| Mar 31 2020 | n/a | n/a | -AU$4m |
| Dec 31 2019 | n/a | n/a | -AU$3m |
| Sep 30 2019 | n/a | n/a | -AU$3m |
| Jun 30 2019 | AU$177k | AU$155k | -AU$3m |
| Mar 31 2019 | n/a | n/a | -AU$2m |
| Dec 31 2018 | n/a | n/a | -AU$2m |
| Sep 30 2018 | n/a | n/a | -AU$2m |
| Jun 30 2018 | AU$160k | AU$142k | -AU$2m |
Compensation vs Market: James's total compensation ($USD505.17K) is about average for companies of similar size in the US market ($USD683.56K).
Compensation vs Earnings: James's compensation has increased whilst the company is unprofitable.
CEO
James Graham
4yrs
Tenure
AU$774,727
Compensation
Mr. James Hamilton-Bray Graham, B.Com. (Entrepreneurship), GAICD, serves as Chief Executive Officer at Recce Pharmaceuticals Ltd since August 28, 2020 and also serves as Managing Director since 2020. He ha...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Chairman of the Board | 6.3yrs | AU$369.85k | 0.14% $ 93.0k | |
| CEO, MD & Executive Director | 4yrs | AU$774.73k | 4.44% $ 3.0m | |
| Chief Scientific Director & Executive Director | 3.9yrs | AU$539.34k | 1.28% $ 857.6k | |
| Principal Quality Chemist & Executive Director | no data | AU$306.76k | 0.14% $ 91.4k | |
| Principal Engineer & Head of Manufacturing | no data | AU$319.12k | 0.030% $ 20.4k | |
| Chief Medical Advisor & Independent Non Executive Director | no data | AU$72.50k | 0.057% $ 38.5k | |
| Chief Financial Officer | 6.8yrs | no data | no data | |
| Head of Marketing | 4.6yrs | no data | no data | |
| Company Secretary | 1.9yrs | no data | no data |
4.0yrs
Average Tenure
Experienced Management: RECE.F's management team is considered experienced (4 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Chairman of the Board | 6.3yrs | AU$369.85k | 0.14% $ 93.0k | |
| CEO, MD & Executive Director | 9.2yrs | AU$774.73k | 4.44% $ 3.0m | |
| Chief Scientific Director & Executive Director | 9.2yrs | AU$539.34k | 1.28% $ 857.6k | |
| Principal Quality Chemist & Executive Director | 5.1yrs | AU$306.76k | 0.14% $ 91.4k | |
| Chief Medical Advisor & Independent Non Executive Director | 4.1yrs | AU$72.50k | 0.057% $ 38.5k | |
| Non-Executive Director | 1.9yrs | AU$392.15k | 0.012% $ 7.9k |
5.7yrs
Average Tenure
Experienced Board: RECE.F's board of directors are considered experienced (5.7 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/08/05 18:08 |
| End of Day Share Price | 2024/05/08 00:00 |
| Earnings | 2023/12/31 |
| Annual Earnings | 2023/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Recce Pharmaceuticals Ltd is covered by 2 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Pooya Hemami | Edison Investment Research |
| Chris Kallos | MST Financial Services Pty Limited |